199 related articles for article (PubMed ID: 32483732)
1. The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma.
Kiany S; Harrison D; Gordon N
Adv Exp Med Biol; 2020; 1257():75-83. PubMed ID: 32483732
[TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.
Rao-Bindal K; Koshkina NV; Stewart J; Kleinerman ES
Curr Cancer Drug Targets; 2013 May; 13(4):411-22. PubMed ID: 23410027
[TBL] [Abstract][Full Text] [Related]
3. The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.
Koshkina N; Yang Y; Kleinerman ES
Adv Exp Med Biol; 2020; 1258():177-187. PubMed ID: 32767242
[TBL] [Abstract][Full Text] [Related]
4. Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases.
Huang G; Nishimoto K; Yang Y; Kleinerman ES
Adv Exp Med Biol; 2014; 804():203-17. PubMed ID: 24924176
[TBL] [Abstract][Full Text] [Related]
5. Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.
Koshkina NV; Rao-Bindal K; Kleinerman ES
Cancer; 2011 Aug; 117(15):3457-67. PubMed ID: 21287529
[TBL] [Abstract][Full Text] [Related]
6. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.
Gordon N; Kleinerman ES
J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):189-96. PubMed ID: 20528149
[TBL] [Abstract][Full Text] [Related]
7. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases.
Gordon N; Kleinerman ES
Cancer Treat Res; 2009; 152():497-508. PubMed ID: 20213411
[TBL] [Abstract][Full Text] [Related]
8. Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone].
Matsubara H; Watanabe M; Imai T; Yui Y; Mizushima Y; Hiraumi Y; Kamitsuji Y; Watanabe K; Nishijo K; Toguchida J; Nakahata T; Adachi S
J Pharmacol Exp Ther; 2009 Mar; 328(3):839-48. PubMed ID: 19073909
[TBL] [Abstract][Full Text] [Related]
9. MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts.
Rao-Bindal K; Zhou Z; Kleinerman ES
Cell Death Dis; 2012 Aug; 3(8):e369. PubMed ID: 22875006
[TBL] [Abstract][Full Text] [Related]
10. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.
Gordon N; Koshkina NV; Jia SF; Khanna C; Mendoza A; Worth LL; Kleinerman ES
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4503-10. PubMed ID: 17671136
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.
Collier CD; Getty PJ; Greenfield EM
Adv Exp Med Biol; 2020; 1258():55-75. PubMed ID: 32767234
[TBL] [Abstract][Full Text] [Related]
13. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
[TBL] [Abstract][Full Text] [Related]
14. The HDAC inhibitor Vorinostat diminishes the in vitro metastatic behavior of Osteosarcoma cells.
Mu X; Brynien D; Weiss KR
Biomed Res Int; 2015; 2015():290368. PubMed ID: 25785263
[TBL] [Abstract][Full Text] [Related]
15. Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells.
Schech A; Kazi A; Yu S; Shah P; Sabnis G
Mol Cancer Ther; 2015 Aug; 14(8):1848-57. PubMed ID: 26037781
[TBL] [Abstract][Full Text] [Related]
16. Entinostat (SNDX-275) for the treatment of non-small cell lung cancer.
Ruiz R; Raez LE; Rolfo C
Expert Opin Investig Drugs; 2015; 24(8):1101-9. PubMed ID: 26098363
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.
McGuire JJ; Nerlakanti N; Lo CH; Tauro M; Utset-Ward TJ; Reed DR; Lynch CC
Int J Cancer; 2020 Nov; 147(10):2811-2823. PubMed ID: 32599665
[TBL] [Abstract][Full Text] [Related]
18. Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.
Maiti A; Qi Q; Peng X; Yan L; Takabe K; Hait NC
Int J Oncol; 2019 Jul; 55(1):116-130. PubMed ID: 31059004
[TBL] [Abstract][Full Text] [Related]
19. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
20. Entinostat for treatment of solid tumors and hematologic malignancies.
Knipstein J; Gore L
Expert Opin Investig Drugs; 2011 Oct; 20(10):1455-67. PubMed ID: 21888556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]